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Previously it was shown that the HHV-8-encoded che-
mokine receptor ORF74 shows considerable agonist-in-
dependent, constitutive activity giving rise to oncogenic
transformation (Arvanitakis, L., Geras-Raaka, E.,
Varma, A., Gershengorn, M. C., and Cesarman, E. (1997)
Nature 385, 347–350). In this study we report that a sec-
ond viral-encoded chemokine receptor, the human cyto-
megalovirus-encoded US28, also efficiently signals in an
agonist-independent manner. Transient expression of
US28 in COS-7 cells leads to the constitutive activation
of phospholipase C and NF-kB signaling via Gq/11 protein-
dependent pathways. Whereas phospholipase C activa-
tion is mediated via Gaq/11 subunits, the activation of
NF-kB strongly depends on bg subunits with a prefer-
ence for the b2g1 dimer. The CC chemokines RANTES
(regulated on activation, normal T cell expressed and
secreted) and MCP-1 (monocyte chemotactic protein-1)
act as neutral antagonists at US28, whereas the CX3C
chemokine fractalkine acts as a partial inverse agonist
with IC50 values of 1–5 nM. Our data suggest that a high
level of constitutive activity might be a more general
characteristic of viral G protein-coupled receptors and
that human cytomegalovirus might exploit this G pro-
tein-coupled receptor property to modulate the homeo-
stasis of infected cells via the early gene product US28.
Viruses have developed a variety of strategies to evade the
immune system, among which is the piracy of cellular genes
that are central to the host defense system (1–3). The identifi-
cation of a variety of viral genes that encode potential G pro-
tein-coupled receptors (GPCRs)1 or GPCR ligands is in this
respect of major interest as the GPCR superfamily is essential
for proper cellular communication (4). In the genome of various
b- and g-herpesviruses, like human cytomegalovirus (HCMV or
HHV-5) (5–7), human herpesviruses HHV-6 (8–10), HHV-7
(11), and HHV-8 (Kaposi’s sarcoma-associated Herpesvirus)
(12–15) viral genes with homology to mammalian chemokines
and/or chemokine receptors have been identified. These obser-
vations suggest that these viruses exploit chemokine signaling
pathways to interfere with the host immune system (1–3).
Currently, the best characterized viral GPCR is ORF74, a
CXCR2 homologue encoded by HHV-8 that binds a variety of
CXC and CC chemokines (16–18). ORF74 signals in a chemo-
kine-independent, constitutively active manner (16–18) and
induces oncogenic transformation when transfected in NIH-
3T3 cells (19). Although constitutive GPCR signaling is now a
well accepted paradigm, the actual physiological relevance is
still not entirely understood (20, 21). HHV-8 is considered to be
the etiologic agent of Kaposi’s sarcoma, a highly vascularized
tumor (22). As transgenic expression of ORF74 also results in
angioproliferative lesions, resembling various symptoms of Ka-
posi’s sarcoma (23), the constitutive activity of ORF74 is one of
the intriguing examples of a potential pathophysiological role
of constitutive GPCR signaling.
In this study we report that a second viral-encoded chemo-
kine receptor, the HCMV-encoded GPCR US28, also efficiently
signals in an agonist-independent manner. The b-herpesvirus
HCMV has been recognized as a risk factor for vascular dis-
eases, like arterial restenosis and atherosclerosis, and causes
life-threatening systemic infections in immunocompromised
patients (24, 25). Sequence analysis of the HCMV genome has
identified four genes encoding GPCRs, US27, US28, UL33, and
UL78 (5), of which US28 is expressed early after viral infection
(26). US28 shows the highest homology (33%) to the CC che-
mokine receptor CCR1 and binds CC chemokines, like RAN-
TES and MCP-1 (6, 27), and the CX3C chemokine fractalkine
(27). US28 shows considerable HIV-I coreceptor activity (28,
29) and is known to enhance in vitro cell-cell fusion mediated
by various viral proteins, including HIV-I envelope proteins
(30). Moreover, US28 has been shown to induce vascular
smooth muscle cell migration (31), which could provide the
molecular basis for the implication of HCMV in atherosclerosis.
In this study, we show that upon transient expression in
COS-7 cells US28 constitutively couples to phospholipase C
and NF-kB via related, though distinct, Gq/11-protein-mediated
mechanisms. Our data suggest that a high level of constitutive
activity might be a more general characteristic of viral GPCRs
and that HCMV might exploit this general GPCR property to
modulate the homeostasis of infected cells via the early gene
product US28.
EXPERIMENTAL PROCEDURES
Materials—ATP disodium salt, bovine serum albumin, chloroquine
diphosphate, DEAE-dextran (chloride form), and pertussis toxin (PTX)
were obtained from Sigma. D-Luciferin was purchased from Duchefa
Biochemie B. V. (Haarlem, The Netherlands). Cell culture media, pen-
icillin, and streptomycin were obtained from Life Technologies, Inc.,
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and fetal calf serum was purchased from Integro B. V. (Dieren, The
Netherlands). myo-[2-3H]Inositol (17 Ci/mmol) was obtained from
PerkinElmer Life Sciences. The human chemokines RANTES (regulat-
ed on activation, normal T cell expressed and secreted), MCP-1 (mono-
cyte chemotactic protein-1), GRO-a, IP-10, and the CX3C chemokine
domain of human fractalkine (residues 1–76) were obtained from Pep-
rotech (Rocky Hill, NJ).
DNA Constructs—pNF-kB-Luc was obtained from Stratagene (La
Jolla, CA). The cDNAs encoding for US28 (encoded by VHL/E HCMV
strain) and US28-N (encoded by AD169 HCMV strain) (GenBankTM
accession numbers L20501 and X17403, bases 219.000–220.263) in-
serted into pcDNA3 were a gift from Dr. R. Doms. The cDNA of the
HHV-8-encoded ORF74 in pTJE8 was a gift from Dr. T. Schwartz. The
cDNA of ORF74 was inserted in pcDNA3 after polymerase chain reac-
tion amplification. Gifts of pcDNA3-based expression vectors containing
the cDNAs of CCR1 (from Dr. C. Tensen), muscarinic m2 receptor (from
Dr. R. Maggio), Gaq (from Dr. B. Conklin), Ga11 and Ga11Q209L (from
Dr. H. Umemori), Gas and Gai2 (from Dr. G. Milligan), Ga16 (from
Dr. S. Rees), Ga12 (from Dr. N. Dhanasekaran), Gat (from Dr. B. De-
fize), Gb1, Gb5, Gg1, and Gg2 (from Dr. M. Lohse), and GRK2 and
GRK2K220R (from Dr. S. Cotecchia) are gratefully acknowledged.
Cell Culture and Transfection—COS-7 cells were grown at 5% CO2 at
37 °C in Dulbecco’s modified Eagle’s medium supplemented with 5%
fetal calf serum, 2 mM L-glutamine, 50 IU/ml penicillin, and 50 mg/ml
streptomycin. Transfection of the COS-7 cells was performed by DEAE-
dextran. The total amount of DNA in transfected cells was maintained
constant by addition of the empty vector.
[3H]Inositol Phosphate Production—Cells were seeded in 24-well
plates, and 24 h after transfection they were labeled overnight in
inositol-free medium (modified Eagle’s medium with Earle’s salts) sup-
plemented with 2 mM L-glutamine, L-cysteine, L-leucine, L-methionine,
L-arginine, glucose, 0.2% bovine serum albumin, and 2 mCi/ml myo-[2-
3H]inositol in the presence or absence of PTX (100 ng/ml). Subse-
quently, the labeling medium was aspirated, cells were washed for 10
min with Dulbecco’s modified Eagle’s medium containing 25 mM
HEPES (pH 7.4), 20 mM LiCl, and incubated for 2 h in the same medium
in the absence or presence of the tested chemokines. The incubation was
stopped by aspiration of the medium and addition of cold 10 mM formic
acid. After 90 min of incubation on ice, inositol phosphates were isolated
by anion exchange chromatography (Dowex AG1-X8 columns, Bio-Rad)
and counted by liquid scintillation.
Reporter-gene Assay—Cells transiently cotransfected with pNFkB-
Luc and either pcDNA3 (mock) or pcDNA3-US28 were seeded in 96-well
black plates (Costar) in serum-free culture medium in the presence or
absence of PTX (100 ng/ml) and the tested chemokines. After 48 h, cells
were assayed for luminescence by aspiration of the medium and addi-
tion of 25 ml of luciferase assay reagent (0.83 mM ATP, 0.83 mM D-
luciferin, 18.7 mM MgCl2, 0.78 mM Na2H2P2O7, 38.9 mM Tris (pH 7.8),
0.39% (v/v) glycerol, 0.03% (v/v) Triton X-100, and 2.6 mM dithiothre-
itol). Luminescence was measured for 3 s in a Wallac Victor2.
Binding Experiments—Cells were seeded in 24-well plates; 48 h after
transfection binding was performed on whole cells for 3 h at 4 °C using
0.1 nM 125I-RANTES in binding buffer (50 mM Hepes, pH 7.4, 1 mM
CaCl2, 5 mM MgCl2, and 0.5% bovine serum albumin). After incubation,
cells were washed four times at 4 °C with binding buffer supplemented
with 0.5 M NaCl. Nonspecific binding was determined in the presence of
0.1 mM cold competitor (RANTES or fractalkine).
Western Blot Analysis—Cells were lysed 48 h after transfection in
RIPA buffer (phosphate-buffered saline containing 1% Nonidet P-40,
0.1% SDS, 0.5% sodium deoxycholate, 1 mM phenylmethylsulpho-
nylfluoride, and 2 mg/ml of aprotinin and leupeptin), sonicated, sepa-
rated by SDS polyacrylamide gel electrophoresis, and blotted to polyvi-
nylidene difluoride membrane. An antibody recognizing the common
motif of Gb (Sigma) was used in combination with a goat anti-rabbit
horseradish peroxidase-conjugated secondary antibody. Protein bands
were detected with ECL chemiluminescence and quantified using an
Imagestation (PerkinElmer Life Sciences).
Statistical Analysis—All data shown are expressed as mean 6 S.E.
Statistical analysis was carried out by Student’s t test. p values , 0.05
were considered to indicate a significant difference.
RESULTS AND DISCUSSION
Expression of the viral chemokine receptor US28 (encoded
by the HCMV VHL/E strain) in COS-7 cells resulted in an
expression-dependent increase in both [3H]inositol phosphate
production and NF-kB activation (Fig. 1A). Expression of the
related US28-N, encoded by the HCMV AD169 strain, gave
similar findings (data not shown). As reported in Ref. 16, the
expression of the HHV-8-encoded oncogenic GPCR ORF74 also
led to a pronounced constitutive activation of phospholipase C
(Fig. 1B). In contrast, expression of the human CCR1 receptor,
which is most homologous to US28 (6), did not result in consti-
tutive or RANTES-mediated phospholipase C activation (Fig.
1B). These findings are in accordance with previous observa-
tions that activation of CCR1 does not result in [3H]inositol
phosphates accumulation in COS-7 cells (32).
The constitutive activity of ORF74 was negatively modulated
by IP-10 and positively by GRO-a (Fig. 1B), thus acting as
inverse agonist and agonist, respectively (17, 18). The US28-
induced signaling was not affected by the CC chemokines RAN-
TES or MCP-1 up to 100 nM but was inhibited by the CX3C
chemokine fractalkine (Fig. 1B). It has been reported that
FIG. 1. US28-mediated induction of NF-kB activity and inositol
phosphates accumulation. A, COS-7 cells (1 3 106 cells) were tran-
siently transfected with increasing amounts of cDNA encoding US28.
48 h after transfection InsP accumulation and NF-kB-driven luciferase
expression were measured. Inset, increase of specific [125I]RANTES
binding to COS-7 cells after transfection of increasing amounts of
US28-cDNA. B, modulation of inositol phosphates accumulation by
various chemokines. COS-7 cells were transiently transfected with
cDNAs encoding US28, ORF74, or the CCR1 receptor (2 mg/106 cells).
Cells were incubated with the indicated chemokines (100 nM), and InsP
production was measured. Data are presented as percentage of control
(mock cells). Representative experiments performed in triplicate are
shown; each experiment was repeated at least twice. The asterisks
indicate a statistically significant difference (p , 0.05) versus receptor
only. FRACT., fractalkine.
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fractalkine binds to US28 (27), but so far no functional activity
of fractalkine at US28 has been described. Fractalkine inhib-
ited the constitutive US28 signaling to phospholipase C by
37 6 4% with an IC50 value of 1.6 6 0.2 nM (n 5 3; Fig. 2). As
the observed inhibition of the US28 signaling is not complete,
fractalkine apparently behaves as a partial inverse agonist (20,
21). The CC chemokines RANTES (100 nM) (Fig. 2, inset) and
MCP-1 (data not shown) antagonized the reduction of basal
US28 signaling by 10 nM fractalkine, thereby acting as neutral
antagonists. RANTES and MCP-1 have previously been shown
to act as agonists at US28 for Gi-dependent signal transduction
(6, 33). These data can be explained by differences in the levels
of constitutive US28 signaling in the different cell systems,
probably as a result of differences in expression of US28 and/or
signaling moieties (20, 21). Because Gi proteins are known
signaling partners for chemokine receptors (34), including
US28 (6, 33), the activation of phospholipase C by US28 could
be due to the release of Gbg subunits, which can activate
phospholipase C isoenzymes (35). Yet, Gai subunits are not
implicated in the US28-mediated constitutive activation of
phospholipase C. PTX treatment did not abolish the US28-
mediated production of [3H]inositol phosphates (103 6 5%; n 5
3), whereas for the muscarinic m2 receptor PTX, treatment
inhibited the carbachol-induced increase in [3H]inositol phos-
phate accumulation for 45 6 1.8%. Coexpression of Gai2 with
US28 did not increase the US28 response (Fig. 3), probably
because of the absence of the bg-sensitive phospholipase Cb2 in
COS-7 cells (32). Instead, coexpression of US28 with either
Ga11 or Gaq enhanced the US28-mediated production of [
3H]i-
nositol phosphates (Fig. 3), whereas coexpression of Ga16 or
Gas did not affect US28 responsiveness. Previously, the recep-
tor kinases GRK2 and -3 have been reported to scavenge both
Gaq/11 subunits (36), as well as bg subunits (37). Coexpression
of US28 with GRK2 or the kinase-deficient GRK2K220R (38)
mutant resulted in an efficient inhibition of US28-mediated
[3H]inositol phosphates production (Fig. 3). In contrast, coex-
pression of the bg-scavenger Gat did not modify constitutive
US28 signaling (Fig. 3).
These data indicate that, in contrast to the homologous CC
chemokine receptor CCR1 (32), US28 interacts with endoge-
nous Gaq/11 subunits in COS-7 cells and thereby constitutively
activates phospholipase C. A large number of GPCRs can also
couple to phospholipase C upon coexpression of Ga16, an hema-
topoietic specific member of the Gq class of proteins (39). Ex-
pression of Ga16 enhanced, for example, the agonist-induced
inositol phosphate production mediated by the muscarinic m2
receptor 2.2-fold, as previously reported (40). However, US28
shows a remarkable level of selectivity for Ga11 and Gaq over
Ga16 for the coupling to phospholipase C in COS-7 cells.
Besides the US28-mediated modulation of phospholipase C
activity, we also observed a constitutive activation of NF-kB
activity upon expression of US28 in COS-7 cells (Fig. 1A). This
effect was not observed for the homologous CCR1 receptor
(data not shown). The constitutive stimulation of NF-kB activ-
ity was not modulated by RANTES or MCP-1 (up to 100 nM;
data not shown), but fractalkine again behaved as an apparent
partial inverse agonist. The US28-mediated increase in NF-kB
FIG. 3. Effect of various Ga subunits on US28-mediated inosi-
tol phosphates accumulation. COS-7 cells were transiently trans-
fected with cDNA encoding US28 (2 mg/106 cells) in the presence of
cDNAs encoding the indicated Ga subunits (2 mg/106 cells) and were
assayed for InsP accumulation after 48 h. Expression of Ga subunits by
themselves did not give a rise in [3H]inositol phosphate production
(data not shown). Inset, the effect of coexpression of GRK2 and the
mutant GRK2K220R or Ga transducin (4 mg/106 cells) on the US28-
mediated InsP production. Data are expressed as percentage of US28-
mediated response. Representative experiments performed in triplicate
are shown, and each experiment was repeated at least three times. The
asterisks indicate a statistically significant difference (p , 0.05) versus
receptor only.
FIG. 2. Inhibition of US28-mediated
inositol phosphates accumulation by
fractalkine. COS-7 cells were tran-
siently transfected with cDNA encoding
US28 (2 mg/106 cells). Cells were incu-
bated with various concentrations of frac-
talkine, and InsP release was measured.
Inset, US28-transfected cells were incu-
bated with fractalkine (10 nM) in the pres-
ence or absence of RANTES (100 nM,
added 10 min prior to fractalkine), and
InsP accumulation was measured. Data
are presented as percentage of US28-me-
diated response and defined as absolute
increase of US28-mediated InsP accumu-
lation above values obtained for mock-
transfected cells. A representative exper-
iment of three experiments, each
performed in triplicate, is shown. The as-
terisk indicates a statistically significant
difference (p , 0.05) versus receptor only.
FRACT., fractalkine.
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activity was reduced by fractalkine for 42 6 4% (n 5 3) with an
IC50 value of 5 6 0.2 nM.
The observed constitutive activation of NF-kB by US28 is of
potential pathophysiological relevance, as NF-kB is an ubiqui-
tously expressed transcription factor that plays a critical role in
the regulation of inducible genes in immune response and
inflammatory events associated with, for example, atheroscle-
rosis (41–43). Activation of NF-kB-mediated transcription has
been reported in human aortic smooth muscle cells after CMV
infection via PTX-sensitive G proteins. Yet, as observed for the
production of [3H]inositol phosphates, Gai is not involved in the
US28-induced increase in NF-kB activity, as PTX treatment
did not affect the US28 response (104 6 5%; n 5 3). Previous
studies have indicated that depending on the cell type and
GPCR, NF-kB-mediated transcription can also be stimulated
following activation of G12/13 or Gq/11 proteins (44). Yet, in
COS-7 cells, only the expression of the activated form of Ga11
(Ga11 Q209L, referred to as Ga11 *) subunits resulted in sig-
nificant activation of NF-kB (Fig. 4A). In line with these find-
ings, coexpression of the wild-type Ga11 or Gaq (Fig. 4A) in-
creased the US28-mediated constitutive NF-kB signaling,
whereas the basal NF-kB activity in mock-transfected cells was
not affected. These observations clearly imply the involvement
of the Gaq/11 proteins in the US28-mediated signaling to NF-
kB. As found for the activation of phosholipase C, GRK2 and its
kinase-deficient mutant inhibited the increase in NF-kB activ-
ity (Fig. 4B, inset). Yet, in contrast to the US28-induced phos-
pholipase C activation, US28-mediated NF-kB activity was
fully inhibited by coexpression of Gat (Fig. 4B). The involve-
ment of bg subunits in constitutive US28 signaling to NF-kB
was further strengthened by coexpression experiments with
various bg subunits (Fig. 5, inset). Of the different combina-
tions tested, only the Gb2 and Gg1 further significantly in-
creased the US28-mediated activation of NF-kB (Fig. 5). These
data corroborate previous findings that GPCRs can show a
clear specificity for specific bg subunit combinations (45).
Whereas US28 activates phospholipase C via Gaq/11 sub-
units, our data suggest that besides aq/11 subunits, bg subunits
are also involved in the NF-kB activation by US28. The appar-
ent coinvolvement of aq/11 and bg subunits suggests that
NF-kB activation is due to bg subunits that are released upon
US28 interaction with Gq/11 proteins, although release of bg
subunits from other G proteins cannot be ruled out. As previ-
ously observed after stimulation of the bradykinin B2 receptor
in Hela cells (44), Gbg subunits appear to be essential but not
exclusive signaling moieties for the NF-kB signaling by US28.
Expression of the various Gbg subunits by themselves did not
increase NF-kB signaling (data not shown). Moreover, our ob-
servation that expression of activated Ga11 initiates NF-kB
signaling indicates that Gaq/11 subunits also trigger a signaling
pathway that converges to NF-kB. Protein kinase C activation
is a likely candidate for this aq/11-mediated pathway (46). Ac-
tivation of NF-kB via bg subunits probably involves the acti-
vation of phosphatidylinositol 3-kinase and Akt (44), two re-
cently identified signaling partners for GPCRs (47, 48).
Additional experiments need to be performed to further delin-
eate the mechanisms of US28-mediated NF-kB activation. The
specific roles of the aq/11 and bg subunits, especially, will re-
quire further clarification.
In conclusion, in comparison to its closest human homologue
FIG. 4. Effect of various Ga subunits on the NF-kB-driven lu-
ciferase expression. A, COS-7 cells were transfected with either
pcDNA3 (MOCK) or US28 (2 mg/106 cells), together with cDNAs encod-
ing different Ga subunits (2 mg/106 cells); 48 h after transfection NF-
kB-driven luciferase expression was measured. B, COS-7 cells were
transiently transfected with US28 (2 mg/106 cells) and increasing
amounts of Gat. RLU, relative light unit. Inset, the effect of coexpres-
sion of GRK2 and the mutant GRK2K220R (2 mg/106 cells) on the
US28-mediated NF-kB activation. Data are expressed as percentage of
control (mock cells). Representative results of three independent exper-
iments performed in triplicate are shown. The asterisks indicate a
significant difference (p , 0.05) versus receptor only.
FIG. 5. Effect of different bg combinations on US28-mediated
NF-kB activation. COS-7 cells were transiently transfected with
US28 (2 mg/106 cells), NF-kB-Luc, and different combinations of Gb1,
b2, and b5 with Gg1 and g2 (2 mg/10
6 cells of each construct); 48 h after
transfection NF-kB-driven luciferase expression was measured. Data
are expressed as percentage of US28-mediated response. A represent-
ative experiment performed in triplicate is shown, and each experiment
was repeated at least three times. The asterisk indicates a significant
difference (p , 0.05) versus receptor only. RLU, relative light unit.
Inset, expression of Gb subunits measured by an antibody directed at a
common motif in Gb .
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CCR1, it is interesting to note that the viral GPCR US28
signals without the need for an agonist and is using a larger
diversity of G proteins and chemokines to affect cellular sig-
naling pathways. For the first time, we show that US28 signals
to phospholipase C via Gaq/11 subunits and NF-kB via both
Gaq/11 and Gbg in a constitutively active manner. It is tempt-
ing to speculate that these characteristics of a promiscuous
GPCR allows US28 to affect a broad range of cells upon CMV
infection. The constitutive activation of the ubiquitous tran-
scription factor NF-kB by the early viral gene product US28
could be of major importance for viral action. US28 has been
shown to cause smooth muscle cell migration upon HCMV
infection without the addition of exogenous chemokines (31).
The basal US28-mediated migration was antagonized for 80%
by neutralizing antibodies against MCP-1, which was released
in an autocrine fashion (31). Constitutive signaling by US28
could be responsible for the remaining migratory response of
the HCMV-infected smooth muscle cells. Moreover, if US28 is
expressed on viral particles, it would also be immediately pres-
ent on the membrane of CMV-infected cells and, by means of its
constitutive activity, could modulate the cellular response. We
also show for the first time a functional response to the CX3C
chemokine fractalkine, i.e. acting as an inverse agonist at
US28. Fractalkine is a quite unique GPCR ligand as its che-
mokine-like domain is linked to a transmembrane segment
(49). Accordingly, fractalkine is membrane-bound, and its in-
teraction with US28 has been suggested to be involved in the
viral transfer between cells (27). The action of fractalkine as an
inverse agonist suggests that inhibition of constitutive US28
activity by fractalkine expressed on the membrane of a target
cell might give the appropriate signal to an CMV-infected,
US28-expressing cell to allow CMV entry into the target cell.
Because no data are currently available on the expression of
US28 on the viral particle or on the role of fractalkine in CMV
infections, future investigations should substantiate these sug-
gestions and indicate if US28 can be regarded as an interesting
drug target in HCMV-related disorders.
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